Our offerings under Regulation D Rule 506(c) are available to accredited investors only.
GENERALLY, NO SALE MAY BE MADE TO YOU IN THIS OFFERING IF THE AGGREGATE PURCHASE PRICE YOU PAY IS MORE THAN 10% OF THE GREATER OF YOUR ANNUAL INCOME OR NET WORTH. DIFFERENT RULES APPLY TO ACCREDITED INVESTORS AND NON-NATURAL PERSONS. BEFORE MAKING ANY REPRESENTATION THAT YOUR INVESTMENT DOES NOT EXCEED APPLICABLE THRESHOLDS, WE ENCOURAGE YOU TO REVIEW RULE 251(D)(2)(I)(C) OF REGULATION A. FOR GENERAL INFORMATION ON INVESTING, WE ENCOURAGE YOU TO REFER TO WWW.INVESTOR.GOV

Hemoanalytics with David C. Karli

In this Show

David C. Karli’s first task was to figure out how to understand what was inside the samples he took before implanting it into a patient. Even though it is the patient’s own tissue and the risk is extremely low, it was sill not good enough for him. Karli and his team investigated technologies to learn what was in the samples, how to measure them, validate their measurements, and control the final product. They called this process hemoanalysis.

 

Get in contact with David C. Karli through his website, LinkedIn, and learn more about Greyledge Technologies here:

davidkarli.com

https://www.linkedin.com/in/davidkarli/

https://www.greyledgebiotech.com/